vitiligo specialist in Hyderabad

Vitiligo isn’t rare, isn’t contagious, and — as of the last few years — isn’t untreatable either. Vitiligo affects roughly 0.5–2% of people worldwide, making it one of the most common pigmentation disorders, yet it remains one of the most misunderstood. It develops when the immune system mistakenly targets melanocytes, the cells that produce melanin, leaving behind smooth, well-defined patches of depigmented skin. It isn’t an infection, a fungus, or a sign of poor hygiene — it’s an autoimmune process, closely related in mechanism to conditions like alopecia areata and autoimmune thyroid disease, which is why the two often appear together in the same person or family. Myths vs. Facts Myth: “Vitiligo is contagious — you can catch it by touch.” Fact: There’s no infectious cause. Vitiligo is autoimmune — the immune system attacks the body’s own pigment-producing cells. There’s no mechanism by which touch, shared utensils, or proximity could transmit it. Myth: “It’s just cosmetic — it doesn’t need real treatment.” Fact: Beyond appearance, vitiligo is linked to a higher likelihood of other autoimmune conditions, particularly thyroid disease, and carries a well-documented psychological toll. That’s exactly why dermatology treats it as a genuine medical condition, not a purely cosmetic one. Myth: “Eating certain food combinations (like fish with milk) causes it.” Fact: There’s no credible evidence linking specific food pairings to onset. The real trigger is autoimmune, often with a genetic predisposition — diet plays no established role. Myth: “There’s nothing modern medicine can do — patches are permanent.” Fact: FDA-approved topical JAK inhibitors, often combined with phototherapy, have produced real, sustained repigmentation in clinical trials — a genuine shift from decades of limited options. Myth: “Only darker skin tones develop vitiligo.” Fact: It occurs across all ethnicities and skin tones at similar rates. It’s simply more visually striking on darker skin, which is likely why the association persists. Myth: “Sun exposure can cure the white patches.” Fact: Unprotected sun exposure doesn’t restore pigment and raises sunburn risk in depigmented areas, since they lack melanin’s natural UV protection. Dermatologists recommend sunscreen on affected patches, not tanning. What’s Actually New in Treatment For decades, options were limited to corticosteroids, calcineurin inhibitors, and phototherapy — each modestly effective at best. That changed with a deeper understanding of the biology: vitiligo progresses largely through interferon-gamma signaling, which recruits immune cells that destroy melanocytes via a chemical messenger called CXCL10. Blocking that pathway directly, rather than just suppressing inflammation broadly, is now the basis of the newest therapies. Topical JAK inhibitors: Ruxolitinib cream, a JAK1/2 inhibitor that interrupts interferon-gamma signaling, became the first FDA-approved repigmenting treatment for non-segmental vitiligo in patients 12 and older, following two phase 3 trials published in the New England Journal of Medicine. Longer-term follow-up out to three years, along with real-world studies published through 2026, shows repigmentation — especially on the face — continuing to improve with sustained use, often better maintained than with older topical options. Combination with phototherapy: Pairing ruxolitinib cream with narrow-band UVB light appears to accelerate and deepen repigmentation compared with either approach alone, according to recent clinical research, making combination regimens increasingly common for stubborn patches. Phototherapy alone: Narrow-band UVB remains a well-established first-line option, particularly for widespread disease, typically requiring sessions over several months under medical supervision. Surgical repigmentation: For small, stable patches that haven’t responded to medical therapy — often seen in segmental vitiligo — techniques such as melanocyte-keratinocyte transplantation can transfer pigment-producing cells from unaffected skin to depigmented areas. Camouflage and psychological support: Medical-grade cosmetic camouflage remains a legitimate, evidence-based option for people seeking coverage without systemic treatment. Because vitiligo carries a well-documented emotional burden, dermatology bodies increasingly recommend connecting patients with counseling or support communities alongside physical treatment. The bigger shift: treatment goals have moved from “manage the disease” to genuine repigmentation, targeted at the immune mechanism itself rather than just calming inflammation — a meaningful change from where dermatology stood even five years ago.